Back to News
Jun 16, 2026 12:00 PM

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday’s session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.

The decision announced on Monday comes after both segments have shown significant advancements, with MRD achieving profitability and expanding its clinical utility, as detailed in the company’s recent announcement regarding its strategic direction to pursue a separation.

MRD And Immune Medicine Business Separation

The commercial-stage biotechnology company is evaluating strategic alternatives for its Immune Medicine segment, which has made strides in drug discovery and data capabilities.

With over 6 million functional T-cell receptor (TCR)-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the disease-causing antigens they bind.

The company expects to finalize its preferred path for separation by the end of 2026, aiming to unlock value ...